Completed PHASE3 INTERVENTIONAL NCT00036153

Study to Assess Efficacy of Tacrolimus + Methotrexate Versus Placebo + Methotrexate in Treatment of Rheumatoid Arthritis

A Randomized, Double-Blind Study to Assess the Efficacy of Tacrolimus (Prograf®)+ Methotrexate Vs. Placebo + Methotrexate in the Treatment of Rheumatoid Arthritis in Patients With Partial Response to Methotrexate

Sponsor: Astellas Pharma Inc

Conditions Rheumatoid Arthritis

Interventions Methotrexate Tacrolimus (Prograf®)

Updated 6 times since 2017 Last updated: Mar 26, 2012 Started: Mar 31, 2002 Completion: Jan 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Rheumatoid Arthritis and is currently completed. Astellas Pharma Inc leads this study, which shows 6 recorded versions since 2002 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Mar 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Astellas Pharma Inc
Astellas Pharma US, Inc.

Data source: Astellas Pharma Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Birmingham, United States , Chicago, United States , Coeur d'Alene, United States , Columbus, United States , Dallas, United States , Danbury, United States , Dayton, United States , Decatur, United States , Duncansville, United States , Erie, United States and 31 more locations